Amneal Pharmaceuticals, Inc announced the approval and launch of fluorometholone ophthalmic suspension. The product received 180-day competitive generic therapy (CGT) exclusivity from the FDA, a status that applies to first-marketed generics of key medicines.
FML® suspension is indicated for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.
“We are starting the new year with the launch of another complex high-value product, which will help drive our continued growth,” said Andy Boyer, Executive Vice President, Chief Commercial Officer - Generics. “Ophthalmic products represent a less crowded and more durable category, and we continue to expand our portfolio of affordable medicines.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!